AR Biosystems

AR Biosystems is a biotechnology company and contract research organization (CRO) based in Rockville, Maryland, focused on the development of novel therapeutics for advanced prostate cancer. The company specializes in targeting the androgen receptor (AR) and its splice variants, particularly AR-V7, which are associated with resistance to standard hormonal therapies. AR Biosystems utilizes its proprietary screening platforms and expertise in molecular biology to identify small molecule inhibitors and degraders of these resistant AR variants. In addition to its internal drug discovery efforts, the company provides specialized research services to the life sciences industry, including protein expression and cell-based assay development. Their research programs have been supported by multiple Small Business Innovation Research (SBIR) grants from the National Cancer Institute.